AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. ROIV
3. ANET
4. NKE
5. PANW
6. CL
7. SNDK
8. TAP
9. DELL
10. EAT

Go back to AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
(NASDAQ: ACIU) Delayed: 2.86 -0.07 (2.39%)
Previous Close $2.93    52 Week High $19.97 
Open $2.91    52 Week Low $10.36 
Day High $2.94    P/E N/A 
Day Low $2.82    EPS $0.00 
Volume 155,628